

TQ-NLC: A POTENTIAL CANDIDATE AS AN ANTIBREAST CANCER AGENT?


Patent No. PI2012001818



THYMOQUINONE-LOADED NANOSTRUCTURED LIPID CARRIER (TQ-NLC)

- Comparable anti-cancer effects with doxorubicin (in animal study)
- Reduced toxic effects (in animal study)
- Possible for drug targeting
- Controlled drug release
- Enhanced bioavailability

DATA




TQ-NLC REDUCED METASTASIS TO THE LUNGS

Group	Survival Percentage (%)	Mean survival time (days)
NLC	56.2	25.0 ± 1.30
TQNLC 25 mg/kg	58.8	24.9 ± 1.05
TQNLC 50 mg/kg	62.5	24.8 ± 1.48
TQNLC 100 mg/kg	81.2	27.6 ± 0.31
Olive oil	60.0	26.7 ± 0.52
TQ 25 mg/kg	64.7	23.9 ± 1.71
TQ 50 mg/kg	73.3	26.5 ± 0.74
TQ 100 mg/kg	53.8	25.7 ± 0.71
Negative	60.0	23.9 ± 1.55
Positive	75.0	27.3 ± 0.41
Normal	100	N.A.

TQ-NLC IMPROVED THE SURVIVAL RATE OF BREAST CANCER-BEARING MICE

BREAST CANCER

- The most common type of cancer in women.
- The incidence is alarming.
- The treatments have side/toxic effects



Project Leader : Assoc. Prof. Dr. Latifah Saiful Yazan
 Co-Researchers : Ng Wei Keat, Ong Yong Sze, Rasedee Abdullah, How Chee Wun, Noordin Mohamed Mustapha
 Faculty : Medicine and Health Sciences
 Email : latifahsy@upm.edu.my
 Tel : +603-89472308
 Expertise : Molecular Biology